Recently, key patents of the core Linker-Payload platform for antibody-drug conjugate (ADC), independently developed by Beijing Sungen Biomedical Technology Co., Ltd., a strategically-controlled subsidiary of Beijing Hotgen Biotech Co., Ltd., have been published under PCT International Publication No. WO2026/086886A by the World Intellectual Property Organization (WIPO). The achievement proves Sungen Biomedical possesses world-leading original innovation capacity in Antibody-Drug Conjugate (ADC) technology and strengthens its technological competitive advantage.
Featuring precise targeting and potent tumor killing effects, ADCs remain a mainstream track in global oncology drug research with accelerated technological upgrades. Optimization of linker-payload systems stands critical to breaking traditional ADC technical bottlenecks and has become a core competition focus across the industry.
Sungen Biomedical’s R&D team has made major breakthroughs through persistent research. The team developed an innovative highly hydrophilic integrated linker-payload platform, delivering core technical support for next-generation ADC development. Centered on unique glycosylated hydrophilic design, the platform resolves molecular aggregation issues caused by hydrophobicity of conventional ADCs and greatly enhances overall drug stability, laying a solid foundation for improved safety and efficacy of ADC therapeutics.
Core strengths of Sungen Biomedical’s proprietary Linker-Payload platform:
1. Modular assembly design. The hydrophilic linker can flexibly combine with payload molecules with diverse anti-tumor mechanisms, enabling rapid development of ADC candidates targeting various tumor types.
2. Superior hydrophilic optimization. Exclusive Hy hydrophilic group dramatically boosts ADC water solubility and optimizes pharmacokinetic profiles.
3. Enhanced molecular stability. The ADC maintains an ultralow non-specific payload release rate in plasma stability tests and steady drug-to-antibody ratio, which optimizes both in vitro and in vivo pharmacological activity.
Backed by global PCT patent layout and fundamental molecular innovation, Sungen Biomedical has established a differentiated ADC technology platform. The company steadily advances multiple ADC pipelines, aims to develop globally competitive next-generation ADC drugs, and drives technological innovation and industrial upgrading in precision oncology treatment.
Incubated by Hotgen Biotech, Sungen Biomedical is an innovation-focused biotech enterprise engaged in discovery, development and commercialization of First-in-Class antibody drugs. Supported by outstanding research capabilities, the firm has built multiple world-class technical platforms. Focusing on unmet clinical needs, it develops promising original macromolecular drug pipelines covering cardiovascular, cerebrovascular and oncological diseases. The company strives to advance high-quality productivity and contribute to global public health.
Updated: May 22, 2026
